Difference between revisions of "Toripalimab (Loqtorzi)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/toripalimab NCI Drug Dictionary]: A humanized immunoglobulin (Ig) G4 monoclo...") |
m |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/toripalimab NCI Drug Dictionary]: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/toripalimab NCI Drug Dictionary]: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | ||
| − | == | + | ==Diseases for which it is established== |
| − | ===[[ | + | *[[Nasopharyngeal carcinoma]] |
| − | + | ==Diseases for which it is used== | |
| − | + | *[[Breast cancer, triple negative]] | |
| + | *[[Clear cell renal cell carcinoma]] | ||
| + | *[[Esophageal squamous cell carcinoma]] | ||
| + | *[[Melanoma]] | ||
| + | *[[Non-small cell lung cancer, nonsquamous]] | ||
| + | *[[Non-small cell lung cancer, squamous]] | ||
| + | *[[Urothelial carcinoma]] | ||
| + | ==History of changes in FDA indication== | ||
| + | *2023-10-27: Approved with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced [[Nasopharyngeal carcinoma|nasopharyngeal carcinoma (NPC)]]. ''(Based on JUPITER-02)'' | ||
| + | *2023-10-27: Approved as a single agent for adults with recurrent unresectable or metastatic [[Nasopharyngeal carcinoma|NPC]] with disease progression on or after a platinum-containing chemotherapy. ''(Based on POLARIS-02)'' | ||
| + | ==History of changes in NMPA indication== | ||
| + | *2018-12-17: Initial approval | ||
| + | *2024-04-11: Approved in combination with axitinib for the first-line treatment of patients with medium- to high-risk unresectable or metastatic [[renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Based on RENOTORCH)'' | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code names:''' JS-001, TAB-001 |
| + | *'''Generic name:''' teriprolizumab, toripalimab-tpzi | ||
| + | *'''Brand name:''' Loqtorzi, Tuoyi | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 13: | Line 27: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Esophageal squamous cell carcinoma medications]] | ||
| + | [[Category:Melanoma medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
| − | + | [[Category:Non-small cell lung cancer, nonsquamous medications]] | |
| − | [[Category: | + | [[Category:Non-small cell lung cancer, squamous medications]] |
| + | [[Category:Urothelial carcinoma medications]] | ||
| + | [[Category:NMPA approved in 2018]] | ||
| + | [[Category:FDA approved in 2023]] | ||
Latest revision as of 01:32, 23 May 2024
Mechanism of action
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is established
Diseases for which it is used
- Breast cancer, triple negative
- Clear cell renal cell carcinoma
- Esophageal squamous cell carcinoma
- Melanoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
- Urothelial carcinoma
History of changes in FDA indication
- 2023-10-27: Approved with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). (Based on JUPITER-02)
- 2023-10-27: Approved as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. (Based on POLARIS-02)
History of changes in NMPA indication
- 2018-12-17: Initial approval
- 2024-04-11: Approved in combination with axitinib for the first-line treatment of patients with medium- to high-risk unresectable or metastatic renal cell carcinoma (RCC). (Based on RENOTORCH)
Also known as
- Code names: JS-001, TAB-001
- Generic name: teriprolizumab, toripalimab-tpzi
- Brand name: Loqtorzi, Tuoyi
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Breast cancer medications
- Esophageal squamous cell carcinoma medications
- Melanoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Urothelial carcinoma medications
- NMPA approved in 2018
- FDA approved in 2023